Objective
to report the 5-year adverse event rates of transcatheter edge-to-edge repair of mitral regurgitation as compared to maximal doses of guideline-directed medical therapy alone
Study
multicentre, open-label, randomised trial
Population
patients with LV-EF of 20 to 50%, moderate-to-severe or severe secondary mitral regurgitation and heart failure
Endpoints
all hospitalisations for heart failure through 5 year follow-up
Conclusion
transcatheter edge-to-edge repair in patients with heart failure and severe mitral regurgitation led to a lower 5-year rate of hospitalisation for heart failure than patients treated with optimal medical treatment
Stone et al. N Engl J Med 2023; 388:2037-48
